


REMARKS

Claims 1-4, 6-8, 10-18, 34-39, 64, 69-74, 76-82, 86, 91-96, 98-104, 108, 113-118, 120-126, and 130-132 were pending. Claims 1-4, 6-8, 10-18, 34-39, 64, 69-74, 76-82, 101-104, 123-126, and 130-132 have been cancelled. Claims 86, 91, 93, 95, 98, 99, 100, 108, 113, 115, 117, 121, and 122 have been amended. Claims 133 and 134 have been added. Therefore, claims 86, 91-96, 98-100, 108, 113-118, 120-122, 133 and 134 will be pending upon entry of the instant amendment.

Claims 86, 91, 93, 95, 98, 99, 100, 108, 113, 115, 117, 121, and 122 have been amended to clarify the invention. Support for new claims 133 and 134 can be found, for example, at least in the claims as originally filed and in the specification at page 26, Table 1. No new matter has been added.


Applicants thank the Examiner for the telephonic interviews between the Examiner and Applicants' attorney regarding the clarification of the compounds which should be included in Groups 1 and 22 on January 19 and 20, 2006. The Examiner clarified that the each of the eight compounds in Group 1, should also be included in



Group 22. In addition, the Examiner clarified that should also be included in Groups 1 and 22.

Response to Restriction Requirement under 35 U.S.C. § 121

The Examiner has required restriction between 29 different inventions under 35 U.S.C. §121. Applicants elect group 22. Group 22 includes claims 86, 91-96, 98-104, 108, 113-118, and 120-126 in part, drawn to a method of treating Parkinson's or Huntington's disease using creatine compounds of the formula:




, with non-cyclic non-phosphate containing substituents, including pharmaceutical salts and an inhibitor of glutamate excitotoxicity, 2,3-dimethoxy-5-methyl-6-decaprenyl benoquinone, nicotinamide, spin traps, growth factors, nitric oxide synthase inhibitors, cyclooxygenase 2 inhibitors, aspirin, ICE inhibitors, neuroimmunophils, N-acetylcysteine, antioxidants, lipoic acid,

cofactors, riboflavin, and CoQ10 neuroprotective agent, classified in class 514 and multiple subclasses.

Response to Species Election

The Examiner has required Applicants to elect, under 35 U.S.C §121, a single disclosed species for prosecution on the merits. Applicants elect creatine. The structure



of creatine is:

It is Applicants' understanding that the species election is for searching purposes only, and upon a finding of allowability of the elected species, the remaining species will be searched.


SUMMARY

Cancellation of and/or amendments to the claims should in no way be construed as an acquiescence to any of the Examiner's objections and/or rejections. The cancellation of/amendments to the claims are being made solely to expedite prosecution of the above-identified application. Applicants reserve the option to further prosecute the same or similar claims in the present or another patent application. The amendments made to the claims are not related to any issues of patentability.

In view of the remarks set forth above, it is respectfully submitted that this application is in condition for allowance. If there are any remaining issues or the Examiner believes that a telephone conversation with Applicants' Attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the Elizabeth A. Hanley, Esq. at (617) 227-7400.

Date: January 23, 2006

LAHIVE & COCKFIELD, LLP
Attorneys at Law

By 

Cynthia M. Soroos, Esq.
Reg. No. 53,623
28 State Street
Boston, MA 02109
(617) 227-7400
(617) 742-4214